Li Xue

Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Multidimensional tumor-blood profiling uncovers systemic lymphocyte-monocyte imbalance in pituitary neuroendocrine tumors.

Multidimensional tumor-blood profiling uncovers systemic lymphocyte-monocyte imbalance in pituitary neuroendocrine tumors.

Journal: Signal transduction and targeted therapy
Published: May 27, 2025

The STUB1-TPIT axis regulates the secretion of adrenocorticotrophic hormone in cushing disease.

The STUB1-TPIT axis regulates the secretion of adrenocorticotrophic hormone in cushing disease.

Journal: Journal of translational medicine
Published: May 05, 2025

X-linked ubiquitin-specific peptidase 11 (USP11) increases susceptibility to Cushing's disease in women.

X-linked ubiquitin-specific peptidase 11 (USP11) increases susceptibility to Cushing's disease in women.

Journal: Acta neuropathologica communications
Published: November 29, 2024

TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas.

TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas.

Journal: Neuro-oncology
Published: November 13, 2024

Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.

Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.

Journal: Neuro-oncology
Published: July 11, 2024

Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis.

Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis.

Journal: International immunopharmacology
Published: January 24, 2024

Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.

Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.

Journal: Acta neuropathologica communications
Published: November 16, 2023

Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors.

Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors.

Journal: Genome medicine
Published: October 14, 2023

Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.

Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.

Journal: Frontiers in endocrinology
Published: January 23, 2023

Pseudocapsule and pseudocapsule-based extracapsular resection in pituitary neuroendocrine tumors.

Pseudocapsule and pseudocapsule-based extracapsular resection in pituitary neuroendocrine tumors.

Journal: Frontiers in endocrinology
Published: September 28, 2022

TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.

TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.

Journal: Neuro-oncology
Published: February 26, 2022

Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches.

Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches.

Journal: Frontiers in endocrinology
Published: September 29, 2021
Showing 1-12 of 12

Last Updated: 09/26/2026